BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...
Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...
Although tolvaptan bests fluid restriction at raising plasma sodium concentration, 19% of patients experience overcorrection ...
In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely ...
This piece explaining the science behind love and loneliness is by Ng Cheng Jie, 17, one of three winners of a nationwide science journalism competition – the Singapore Biology Reporting Challenge.
Clinicians now have an FDA-approved liquid desmopressin option for central diabetes insipidus, designed for dosing consistency across the age spectrum.
Retex Pharmaceuticals Inc. has patented vasopressin V2 receptor antagonists potentially useful for the treatment of hyponatremia, cardiovascular disorders, autosomal dominant and autosomal recessive ...
Nocturia, the urge to wake from sleep to void, is targeted sub-optimally by existing drugs that modulate circadian dysregulation of urine production in kidney without alleviating detrusor overactivity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results